Axcella Health Stock Price, News & Analysis

Axcella (Nasdaq: AXLA) announced plans to report its fourth quarter and full year 2020 financial results on March 17, 2021. The company will host a conference call at 8:30 a.m. ET, with details available on its website. Axcella focuses on treating complex diseases using endogenous metabolic modulator (EMM) compositions. Its pipeline includes candidates targeting non-alcoholic steatohepatitis (NASH) and the recurrence of overt hepatic encephalopathy (OHE).

Axcella (Nasdaq:AXLA) has appointed Dr. Alison D. Schecter as President of Research and Development, overseeing clinical and regulatory efforts as the company enters late-stage development with its lead candidates. Dr. Schecter brings over 20 years of experience, previously serving at Selecta Biosciences and Sanofi-Genzyme. Manu Chakravarthy has stepped down as Chief Medical Officer. Axcella is working on innovative therapies for complex diseases, including non-alcoholic steatohepatitis (NASH) and hepatic encephalopathy (OHE).

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company, has announced three presentations at the NASH-TAG 2021 Conference on March 11-13. The highlights include clinical data on AXA1125, a candidate for nonalcoholic steatohepatitis (NASH), which is advancing into Phase 2b trials. Presentations will cover mechanistic insights into AXA1125 and its biological activity regarding glucose, insulin, liver fat, and fibroinflammation in subjects with NAFLD and type 2 diabetes. Nadege T. Gunn, M.D. will receive a Distinguished Abstract and Poster Award during the event.

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company, announced its participation in several upcoming investor conferences. The events include the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021, H.C. Wainwright Global Life Sciences Conference on March 9, 2021, and the 33rd Annual Roth Conference on March 15, 2021. Webcasts of these presentations will be available on the company’s website for 90 days. Axcella focuses on treating complex diseases using endogenous metabolic modulator compositions, with candidates targeting non-alcoholic steatohepatitis and hepatic encephalopathy.

Axcella (Nasdaq: AXLA) announced the FDA's clearance of its first investigational new drug (IND) filing, enabling the advancement of AXA1665 into Phase 2 trials. The company reported positive data from previous studies on AXA1665 and AXA1125, indicating their potential in treating overt hepatic encephalopathy (OHE) and nonalcoholic steatohepatitis (NASH) respectively. AXA1665's Phase 2 trial aims to enroll approximately 150 patients and assess its efficacy in reducing OHE risk. Axcella plans to expand its pipeline with further clinical trials slated for 2021.

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company, announced its participation in the J.P. Morgan 2021 Healthcare Conference, scheduled for January 14, 2021, at 10:00 a.m. ET. The event will feature a live audio webcast available on the company’s website, with a replay accessible for 90 days post-presentation. Axcella focuses on treating complex diseases using endogenous metabolic modulator (EMM) compositions. Its pipeline includes candidates for non-alcoholic steatohepatitis (NASH) and reducing the risk of overt hepatic encephalopathy recurrence.

Axcella (NASDAQ: AXLA) presented data at The Liver Meeting® 2020 regarding AXA1125, a treatment candidate for nonalcoholic steatohepatitis (NASH). The clinical study, AXA1125-003, involved 102 subjects and showed promising results in safety and efficacy over 16 weeks. Key findings included significant reductions in metabolic markers and liver function indicators for patients receiving AXA1125 compared to placebo. Axcella aims to further explore AXA1125's impact on liver histology in an upcoming Phase 2b trial targeting biopsy-proven NASH.

Axcella (AXLA) reported its third-quarter financial results for 2020, showcasing significant advancements amidst the COVID-19 pandemic. The company successfully completed a Type B pre-IND meeting with the FDA for AXA1125, advancing towards an IND application and a Phase 2b trial for nonalcoholic steatohepatitis (NASH). Positive top-line data were also presented for AXA1665, targeting hepatic encephalopathy recurrence. Axcella's cash position improved to $117.3 million, and net losses decreased compared to the previous year. The company plans to initiate additional trials in 2021.

Axcella (AXLA), a clinical-stage biotechnology firm, will report its Q3 financial results and business updates on November 12, 2020. The conference call will begin at 8:30 a.m. ET and can be accessed via telephone or through a webcast on Axcella's website. The company focuses on treating complex diseases using endogenous metabolic modulator compositions, with lead candidates targeting non-alcoholic steatohepatitis and hepatic encephalopathy. Investors are encouraged to monitor the company's website for updates and disclosures.